Patents by Inventor Mimin LIU

Mimin LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MiRNA marker for diagnosis and/or treatment of alzheimer's disease
    Patent number: 12006551
    Abstract: A miRNA marker for the treatment and/or diagnosis of Alzheimer's disease (AD), and the miRNA marker is a miRNA23 cluster. The miRNA23 cluster is used in the diagnosis and treatment of AD. The expression of the miRNA23 cluster is detected using primers for the microRNA marker through AD model cells, AD model animals and natural aging animals, and blood of AD patients, and it is found that the expression of the miRNA23 cluster is significantly reduced during the progression of AD, which reduces neuronal apoptosis by inhibiting the GSK-3?-mediated tau protein phosphorylation. Therefore, the miRNA23 cluster can be used as a novel biomarker and therapeutic target for the early, non-invasive diagnosis and treatment of AD.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: June 11, 2024
    Assignee: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking University
    Inventors: Rui Liu, Zhuorong Li, Li Zeng, Ting Sun, Mimin Liu, Junxia Zhang
  • miRNA MARKER FOR DIAGNOSIS AND/OR TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20220259658
    Abstract: The disclosure provides a miRNA marker for the treatment and/or diagnosis of Alzheimer's disease (AD), and the miRNA marker is a miRNA23 cluster. The disclosure provides use of the miRNA23 cluster in the diagnosis and treatment of AD. The expression of the miRNA23 cluster is detected using primers for the microRNA marker through AD model cells, AD model animals and natural aging animals, and blood of AD patients, and it is found that the expression of the miRNA23 cluster is significantly reduced during the progression of AD, which reduces neuronal apoptosis by inhibiting the GSK-3?-mediated tau protein phosphorylation. Therefore, the miRNA23 cluster can be used as a novel biomarker and therapeutic target for the early, non-invasive diagnosis and treatment of AD.
    Type: Application
    Filed: April 14, 2020
    Publication date: August 18, 2022
    Applicant: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINES ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL
    Inventors: Rui LIU, Zhuorong LI, Li ZENG, Hailun JIANG, Ting SUN, Mimin LIU, Junxia ZHANG